Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing

Whole exome sequencing (WES) is used to identify mutations in a patient’s tumor DNA that are predictive of tumor behavior, including the likelihood of response or resistance to cancer therapy. WES has a mutation limit of detection (LoD) at variant allele frequencies (VAF) of 5%. Putative mutations c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yan Helen, Chen, Sherry X., Cheng, Lauren Y., Rodriguez, Alyssa Y., Tang, Rui, Cabrera, Karina, Zhang, David Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172533/
https://www.ncbi.nlm.nih.gov/pubmed/34079006
http://dx.doi.org/10.1038/s41598-021-91142-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172533/
https://www.ncbi.nlm.nih.gov/pubmed/34079006
http://dx.doi.org/10.1038/s41598-021-91142-1

Ejemplares similares